Schedule 13D ownership disclosure

ArriVent Biopharma Inc

Common Stock · CUSIP: 04272N102

Event date: 2025-08-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ADVISORS LLCReported CIK 0001055951

    Shares: 3,027,328.00 · Class: 7.5%

  • OrbiMed Capital GP VIII LLCReported CIK 0001845804

    Shares: 1,513,664.00 · Class: 3.7%

  • OrbiMed Asia GP IV, L.P.Reported CIK 0001966836

    Shares: 1,513,664.00 · Class: 3.7%

  • OrbiMed Advisors IV LimitedReported CIK 0001966835

    Shares: 1,513,664.00 · Class: 3.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000764
Form type
SCHEDULE 13D/A
Filer
ArriVent BioPharma, Inc.
CIK
CIK 1868279
Filed
Aug 13, 2025
Reporting period
Aug 11, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub